+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.

Age: 18Years - 80YearsAll GendersPhase 3
61 locations
E

Actively Recruiting

Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.

Age: 18Years +All GendersPhase 3
119 locations
S

Actively Recruiting

Researchers are conducting a multicenter, prospective observational study across 200 hospitals in China to examine current treatment patterns for chronic hepatitis B CHB. The study aims to compare patient outcomes under different treatment regimens to provide evidence-based data that can improve CHB treatment strategies and follow-up care, ultimately advancing efforts toward a functional cure for chronic hepatitis B. Participants include those receiving or planned to receive treatments such as entecavir ETV, tenofovir disoproxil fumarate TDF, tenofovir alafenamide fumarate TAF, tenofovir amibufenamide TMF, or peginterferon alpha-2b injection. The study observes real-world clinical practice without assigning treatments, capturing data on these therapies over an extended period. During the study, researchers will monitor outcomes including the percentage of patients developing HBsAg-associated hepatocellular carcinoma HCC, incidence of HCC, rates of HBsAg seroclearance and seroconversion, changes in HBsAg levels, HBV DNA levels, liver fibrosis improvement, and liver-related complications. Data collection spans from week 4 up to week 240, with continuous follow-up to assess treatment effects and patient status over time.

Age: 18Years +All Genders
162 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Peripheral Scoring Drug-coated Balloon dilatation catheters in treating stenosis of arteriovenous fistulas used for hemodialysis. This prospective, multi-center, single-arm clinical study plans to enroll 328 participants who have mature arteriovenous fistulas or grafts with significant narrowing. The study aims to measure how well the treated blood vessel remains open, focusing on the primary patency of the target lesion six months after the procedure. Participants will receive treatment using the Dissolve AV Peripheral Scoring Drug-coated Balloon dilatation catheter during a surgical procedure. After treatment, participants will have follow-up visits within 5 days, then at 1 month, 6 months, and later at 12, 18, and 24 months to monitor the treated area. The primary goal is to assess the blood vessels openness at 6 months, with additional checks extending up to two years to evaluate longer-term outcomes. During the study, participants will undergo various assessments including Doppler ultrasound to measure blood flow and detect restenosis, evaluations of clinical success shortly after the procedure, and checks for the need for further revascularization treatments. Safety and technical success of the device will also be monitored immediately after the intervention. The total participation time spans up to 24 months, allowing detailed observation of the devices performance and the participants vascular health over time.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
33 locations
E

Actively Recruiting

Researchers are evaluating the effect, safety, and cost-effectiveness of low-sodium salt substitutes in reducing blood pressure and preventing hypertensive disorders in pregnant women at high risk in China. This study will enroll about 3,200 pregnant women at or before 16 weeks of gestation from multiple hospitals across several provinces. The trial uses an adaptive two-phase design, with an interim analysis after the first 400 participants to decide on continuation and sample size adjustments. Participants will be randomly assigned in equal groups to either use a potassium-enriched salt substitute containing 25% potassium chloride and 75% sodium chloride or continue using usual salt with over 99% sodium chloride. The assigned salt will be provided free of charge and used for home-prepared meals until delivery. Follow-up will continue through all antenatal visits and delivery to collect blood pressure data and monitor the incidence of hypertensive disorders and related adverse events. Participants will attend regular antenatal check-ups where blood pressure and other health data will be collected. The primary outcomes include the change in systolic blood pressure from baseline to about 36-37 weeks gestation and the incidence of new hypertensive disorders and maternal adverse events from randomization to delivery. Researchers will also assess safety, adherence, and cost-effectiveness during the study, which continues until delivery for each participant.

Age: 18Years +FEMALEPhase Not Applicable
110 locations
E

Actively Recruiting

Researchers are evaluating the use of transcutaneous electrical acupoint stimulation TEAS to help adults recover more quickly after laparoscopic surgery for stomach cancer. This randomized, sham-controlled trial compares real TEAS with a sham treatment to see if TEAS can speed up digestive recovery, reduce pain, and decrease the need for extra pain medication. The study involves 104 adults aged 18 to 80 years undergoing surgery for stage I-III gastric cancer at multiple hospitals in Shandong Province, China. Participants are randomly assigned to receive either real TEAS or a sham treatment using a specialized device. TEAS is applied to four pairs of acupoints on the skin starting 2 hours after waking from anesthesia and then once daily for three days after surgery. Each session lasts 30 minutes. Both groups receive the same standard enhanced recovery care and pain management, including patient-controlled intravenous analgesia with sufentanil and flurbiprofen axetil, plus rescue morphine if needed. Throughout the study, participants rate their pain at several time points up to 72 hours after surgery and complete quality-of-life and fatigue questionnaires before surgery, on day 4 after surgery, and 30 days later. Researchers monitor recovery by measuring time to first flatus, bowel movements, diet tolerance, pain scores, analgesic use, ambulation, hospital stay length, and postoperative complications. Blood samples are collected to analyze inflammatory and gastrointestinal markers. Follow-up includes a visit or phone call 30 days after hospital discharge to assess outcomes and safety.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
8 locations
C

Actively Recruiting

Researchers are evaluating whether transcutaneous electrical acupoint stimulation TEAS, a treatment using mild electrical pulses through skin pads without needles, can help people recover faster after laparoscopic surgery for stomach cancer. The study compares three groups to see if TEAS given before, during, and after surgery works better than only after surgery or not at all. The trial involves adults aged 18 to 80 with stage I-III gastric cancer undergoing laparoscopic radical gastrectomy. Participants are randomly assigned to one of three groups one receives TEAS before, during, and after surgery another gets sham inactive treatment before and during surgery and real TEAS after the third group receives sham treatment at all times. TEAS targets four specific acupoints using a standardized device and is applied for 30 minutes before anesthesia, throughout surgery, and 30 minutes daily for three days after surgery. All participants also receive standard enhanced recovery protocols and pain management. During the study, participants will rate their pain at several time points up to 72 hours after surgery and complete quality-of-life and fatigue questionnaires before surgery, on day 4, and 30 days post-surgery. Researchers will measure time to first gas passage, pain scores, pain medication use, gastrointestinal recovery markers, hospital stay length, and safety outcomes. Blood samples will be collected to analyze inflammatory and immune markers. Follow-up occurs by visit or phone call 30 days after hospital discharge, with safety and compliance overseen by an independent committee.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
13 locations
E

Actively Recruiting

Researchers are investigating the best approach to treat acute ischemic stroke caused by large vessel occlusion LVO, a leading cause of disability. Mechanical thrombectomy MT is the current standard treatment, but the role of intravenous thrombolysis before MT is unclear. This phase 3 randomized trial evaluates different thrombolysis strategies using tenecteplase or reteplase compared with direct MT alone in adults presenting within 4.5 hours of stroke onset with confirmed anterior circulation LVO. Participants will be randomly assigned to one of three groups tenecteplase plus MT, reteplase plus MT, or direct MT without thrombolysis. Tenecteplase is given as a single intravenous bolus dose of 0.25 mgkg, while reteplase is administered as two 18 mg bolus injections separated by 30 minutes. Mechanical thrombectomy is performed according to standard practice. The study aims to determine if bridging thrombolysis improves functional independence at 90 days after treatment, with further comparison between the two thrombolytic agents if superiority is found. Throughout the study, participants will be assessed for functional outcomes, neurological improvement, reperfusion success, quality of life, and safety measures up to 90 days after randomization. Assessments include imaging, clinical evaluations, and monitoring for complications such as bleeding or mortality. The primary outcome is achieving functional independence, defined by a modified Rankin Scale score of 0 to 2 at 90 days. The total study duration extends to the final follow-up at 90 days post-treatment.

Age: 18Years +All GendersPhase 3
5 locations